Bausch + Lomb (BLCO) Competitors $14.90 -0.33 (-2.17%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$14.85 -0.05 (-0.34%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. ZBH, SNN, SOLV, PEN, STVN, IRTC, GKOS, SLNO, TMDX, and NVSTShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Zimmer Biomet Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos Soleno Therapeutics TransMedics Group Envista Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Do analysts prefer BLCO or ZBH? Bausch + Lomb presently has a consensus price target of $15.56, indicating a potential upside of 4.40%. Zimmer Biomet has a consensus price target of $111.00, indicating a potential upside of 12.02%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18Zimmer Biomet 2 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.39 Which has more risk & volatility, BLCO or ZBH? Bausch + Lomb has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Is BLCO or ZBH more profitable? Zimmer Biomet has a net margin of 10.51% compared to Bausch + Lomb's net margin of -5.58%. Zimmer Biomet's return on equity of 12.76% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-5.58% 2.33% 1.12% Zimmer Biomet 10.51%12.76%7.21% Does the media refer more to BLCO or ZBH? In the previous week, Zimmer Biomet had 8 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Zimmer Biomet and 9 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.09 beat Bausch + Lomb's score of 0.65 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 13 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, BLCO or ZBH? Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.79B1.10-$317M-$0.78-19.10Zimmer Biomet$7.68B2.56$903.70M$4.1124.11 Do insiders and institutionals believe in BLCO or ZBH? 11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.2% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryZimmer Biomet beats Bausch + Lomb on 16 of the 16 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$5.39B$7.50B$5.73B$21.51BDividend YieldN/A2.86%5.90%3.50%P/E Ratio-19.1074.3076.3929.83Price / Sales1.1036.41527.1553.44Price / Cash8.1324.1937.1724.76Price / Book0.807.2013.304.53Net Income-$317M$241.92M$3.28B$998.53M7 Day Performance-0.96%2.64%0.88%1.09%1 Month Performance2.62%3.32%4.67%4.39%1 Year Performance-19.76%2.21%76.59%13.83% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb2.2038 of 5 stars$14.90-2.2%$15.56+4.4%-16.3%$5.39B$4.79B-19.1013,500Positive NewsZBHZimmer Biomet4.8259 of 5 stars$104.74-0.9%$111.00+6.0%-7.7%$20.94B$7.68B25.4817,000Positive NewsSNNSmith & Nephew SNATS3.1364 of 5 stars$38.38+0.8%$36.00-6.2%+18.7%$16.68B$5.81B17.7717,349SOLVSolventum2.0226 of 5 stars$74.62+2.6%$85.75+14.9%+3.3%$12.61B$8.25B34.5522,000Analyst ForecastPENPenumbra4.723 of 5 stars$285.15+1.3%$302.93+6.2%+40.2%$10.98B$1.19B75.844,500STVNStevanato GroupN/A€25.53+5.7%N/A+42.3%€7.73B€1.19B47.285,521Gap UpIRTCiRhythm Technologies1.2039 of 5 stars$187.07+3.3%$163.82-12.4%+136.6%$5.82B$591.84M-63.852,000Positive NewsGKOSGlaukos4.6345 of 5 stars$91.83-2.2%$127.42+38.7%-33.7%$5.39B$383.48M-55.66780Positive NewsSLNOSoleno Therapeutics4.4324 of 5 stars$72.30+3.6%$115.09+59.2%-5.8%$3.71BN/A-17.4630Short Interest ↑TMDXTransMedics Group2.6291 of 5 stars$105.58+1.5%$122.11+15.7%-21.2%$3.55B$441.54M54.70210Analyst ForecastNVSTEnvista3.817 of 5 stars$21.14-0.8%$20.92-1.0%+11.5%$3.54B$2.51B66.0512,300Positive News Related Companies and Tools Related Companies Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors iRhythm Technologies Competitors Glaukos Competitors Soleno Therapeutics Competitors TransMedics Group Competitors Envista Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLCO Stock Alerts